IGA NEPHROPATHY

This study tests whether hydroxychloroquine, a drug already used for lupus, can slow kidney damage in people with IgA nephropathy (Berger's disease). About 334 adults in France will receive either the drug or a placebo for several months. The goal is to see if it helps preserve k…

This early-phase study tests a new treatment called anti-CD19/BCMA universal CAR T cells for people with relapsed or refractory immune-mediated kidney disease. The therapy uses specially engineered immune cells to target and destroy harmful B cells that drive the disease. The mai…

This study tests a new drug, JADE101, in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants must be on stable standard care and have a kidney biopsy confirming the dis…

This study tests whether combining budesonide and ambrisentan can lower protein levels in urine and slow kidney function decline in people with IgA nephropathy, a chronic kidney disease. About 129 adults with mild to moderate kidney damage will receive both drugs for 36 weeks. Th…

This early-stage study tests whether a new drug called BHV-1400 is safe and tolerable for people with IgA nephropathy, a kidney disease. About 20 adults with confirmed IgA nephropathy will receive the drug and be monitored for side effects. The main goal is to check safety, not y…

This study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…

This study looks at whether continuing TARPEYO (budesonide) for up to 19 months helps adults with IgA nephropathy, a kidney disease. Participants have already taken the drug for 9 months. Researchers will check urine and blood tests to see if the drug keeps working safely. About …

This study tests an experimental drug called EVER001 in 45 adults with three types of kidney disease (FSGS, MCD, or IgAN) that cause protein to leak into urine. Participants take two capsules twice daily for 52 weeks. The goal is to see if the drug safely reduces protein levels a…

This program provides access to EXV811, atrasentan for people with IgA nephropathy, a serious kidney disease. It is for patients who have no other treatment options and cannot join a clinical trial. The goal is to offer potential benefit when standard therapies are not available.

This study follows 2000 people with IgA nephropathy who still have good kidney function. Researchers will test blood and urine samples to find biomarkers that might predict if and when kidney disease gets worse. The goal is to better understand the disease, not to test a new trea…

This study follows 800 adults with IgA nephropathy, a kidney disease, to see how well current treatments work in everyday medical practice. Researchers want to understand why some patients still have protein in their urine or worsening kidney function despite standard care. The g…